CA
NZ
UK
AU
IND
US
…
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 542.38M | 475.92M | 335.68M | 282.86M | 201.85M |
| Net income | 451.12M | 404.39M | 282.81M | 245.37M | 181.85M |
| Selling general administrative | 197.56M | 178.68M | 159.85M | 131.40M | 108.42M |
| Selling and marketing expenses | - | 1.50M | 1.50M | - | - |
| Gross profit | 760.62M | 656.30M | 524.50M | 432.44M | 328.15M |
| Reconciled depreciation | 28.12M | 29.25M | 25.25M | 22.34M | 21.12M |
| Ebit | 542.38M | 475.92M | 336.17M | 278.70M | 198.62M |
| Ebitda | 570.50M | 505.17M | 362.50M | 301.04M | 219.73M |
| Depreciation and amortization | 28.12M | 29.25M | 26.33M | 22.34M | 21.12M |
| Non operating income net other | - | - | - | 7.07M | 3.34M |
| Operating income | 534.93M | 446.87M | 336.82M | 278.70M | 198.62M |
| Other operating expenses | 1995.30M | 1662.18M | 1549.02M | 1181.30M | 943.76M |
| Interest expense | - | 25.00M | 0.49M | 2.90M | -0.10M |
| Tax provision | 91.25M | 71.54M | 45.44M | 37.49M | 20.00M |
| Net interest income | 12.78M | 25.00M | -3.16M | -2.90M | -0.10M |
| Income tax expense | 91.25M | 71.54M | 52.87M | 37.49M | 20.00M |
| Total revenue | 2530.23M | 2109.05M | 1885.84M | 1460.00M | 1142.38M |
| Total operating expenses | 225.68M | 209.44M | 187.68M | 153.74M | 129.54M |
| Cost of revenue | 1769.62M | 1452.75M | 1361.34M | 1027.56M | 814.22M |
| Total other income expense net | 7.44M | 29.05M | -1.14M | 4.16M | 3.24M |
| Net income from continuing ops | 451.12M | 404.39M | 273.18M | 245.37M | 181.85M |
| Net income applicable to common shares | - | - | - | 245.37M | 181.85M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1975.47M | 2100.87M | 1656.83M | 1352.49M | 1659.93M |
| Intangible assets | 33.42M | 34.37M | 35.81M | 38.01M | 41.36M |
| Other current assets | 90.50M | 63.35M | 49.98M | 52.29M | 43.18M |
| Total liab | 1516.40M | 1275.32M | 1097.88M | 966.11M | 707.01M |
| Total stockholder equity | 459.07M | 825.54M | 558.95M | 386.39M | 952.93M |
| Deferred long term liab | - | - | - | 1.07M | 1.08M |
| Other current liab | 438.01M | 338.15M | 40.44M | 257.67M | 27.61M |
| Common stock | 0.28M | 0.31M | 0.31M | 0.31M | 0.36M |
| Capital stock | 0.28M | 0.31M | 0.31M | 0.31M | 0.36M |
| Retained earnings | -459.98M | 8.17M | -221.65M | -359.83M | 234.98M |
| Other liab | - | - | - | 23.77M | 18.82M |
| Good will | 662.40M | 662.40M | 662.40M | 662.40M | 662.40M |
| Other assets | - | - | - | 69.21M | 42.56M |
| Cash | 497.05M | 669.44M | 245.45M | 28.27M | 461.30M |
| Total current liabilities | 1343.75M | 1104.55M | 925.13M | 803.47M | 557.22M |
| Current deferred revenue | 854.39M | 710.59M | 559.86M | 462.73M | 344.64M |
| Net debt | -246.55M | -519.91M | -103.33M | 160.60M | -330.34M |
| Short term debt | 23.21M | 23.29M | 292.96M | 50.00M | 159.29M |
| Short long term debt | - | - | - | 50.00M | - |
| Short long term debt total | 250.50M | 149.52M | 142.12M | 188.87M | 130.97M |
| Other stockholder equity | 923.67M | 831.82M | 790.36M | 758.30M | 722.43M |
| Property plant equipment | - | - | - | 109.85M | 93.15M |
| Total current assets | 989.62M | 1029.23M | 593.83M | 333.96M | 690.91M |
| Net tangible assets | - | - | - | -314.02M | 249.17M |
| Net receivables | 402.08M | 296.44M | 298.40M | 253.40M | 186.43M |
| Inventory | - | - | 0.00M | - | - |
| Accounts payable | 28.14M | 32.53M | 31.87M | 33.07M | 25.68M |
| Accumulated other comprehensive income | -4.91M | -14.74M | -10.07M | -12.39M | -4.85M |
| Common stock total equity | - | - | - | 0.31M | 0.36M |
| Retained earnings total equity | - | - | - | -359.83M | 234.98M |
| Treasury stock | - | - | - | -12.50M | -5.43M |
| Non currrent assets other | 21.94M | 22.25M | 24.97M | 21.13M | 17.42M |
| Non current assets total | 985.85M | 1071.64M | 1063.00M | 1018.53M | 969.02M |
| Capital lease obligations | 113.64M | 126.23M | 142.12M | 138.87M | 130.97M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -28.31M | -35.85M | -38.74M | -31.36M |
| Change to liabilities | - | - | - | 58.91M | 28.02M |
| Total cashflows from investing activities | -31.14M | -28.31M | -34.63M | -38.74M | -31.36M |
| Net borrowings | 0.00M | 0.00M | -50.00M | 50.00M | 50.00M |
| Total cash from financing activities | -860.39M | -154.01M | -182.64M | -775.77M | -44.45M |
| Change to operating activities | - | - | - | 48.46M | 0.85M |
| Net income | 451.12M | 404.39M | 282.81M | 245.37M | 181.85M |
| Change in cash | -172.39M | 423.99M | 217.18M | -433.04M | 183.54M |
| Begin period cash flow | 669.44M | 245.45M | 28.27M | 461.30M | 277.77M |
| End period cash flow | 497.05M | 669.44M | 245.45M | 28.27M | 461.30M |
| Total cash from operating activities | 713.22M | 608.82M | 433.37M | 388.05M | 263.33M |
| Depreciation | 27.18M | 29.25M | 26.33M | 22.34M | 21.12M |
| Other cashflows from investing activities | 0.22M | 8.24M | 2.02M | -1.86M | -3.09M |
| Dividends paid | - | - | 11.38M | - | - |
| Change to inventory | - | - | 66.19M | - | 24.98M |
| Change to account receivables | -106.22M | 2.24M | -48.28M | -66.92M | -24.98M |
| Sale purchase of stock | -917.39M | -169.87M | -144.02M | -847.85M | -62.10M |
| Other cashflows from financing activities | -860.39M | 15.86M | 11.38M | 346.27M | 17.64M |
| Change to netincome | - | - | - | -3.11M | -21.97M |
| Capital expenditures | 31.36M | 36.55M | 36.65M | 36.88M | 28.27M |
| Change receivables | - | - | - | -66.92M | -24.98M |
| Cash flows other operating | - | - | - | 131.46M | 79.29M |
| Cash and cash equivalents changes | - | - | - | -426.47M | 187.51M |
| Change in working capital | 96.28M | 157.18M | 106.49M | 106.06M | 66.71M |
| Stock based compensation | 34.79M | 25.51M | 20.52M | 21.41M | 14.47M |
| Other non cash items | 23.09M | 19.11M | 22.35M | 15.89M | 16.30M |
| Free cash flow | 681.87M | 572.27M | 396.73M | 351.17M | 235.06M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MEDP Medpace Holdings Inc |
18.89 2.80% |
692.68 | 35.00 | 32.05 | 6.22 | 39.89 | 6.08 | 27.69 |
| TMO Thermo Fisher Scientific Inc |
11.13 1.61% |
704.15 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
2.07 0.89% |
234.07 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
- -% |
23.25 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
0.45 1.90% |
24.19 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
| Name | Title | Year Born |
|---|---|---|
| Dr. August James Troendle M.D. | Chairman & CEO | 1956 |
| Mr. Jesse J. Geiger BBA, CPA | Pres | 1974 |
| Mr. Kevin M. Brady | CFO & Treasurer | 1974 |
| Ms. Susan E. Burwig | Exec. VP of Operations | 1963 |
| Mr. Stephen P. Ewald | Chief Compliance Officer, Gen. Counsel & Corp. Sec. | 1969 |
| Brandon Ebken | Chief Information Officer | NA |
| Ms. Lauren Morris | Associate Director of Investors Relations | NA |
| Mr. Todd Meyers | VP of Bus. Devel. & Marketing | NA |
| Mr. Weimin Gai MS | Sr. VP of Biometrics | NA |
| Mr. Daniel O'Leary | Sr. VP of Medical Department | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.02%
Communication Services
-0.63%
Consumer Cyclical
-0.11%
Consumer Defensive
-0.45%
Energy
+0.39%
Financial Services
-0.10%
Financials
-0.81%
Healthcare
+1.03%
Industrials
+0.32%
Real Estate
-0.31%
Technology
+0.59%
Utilities
-0.18%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...